What Amaran Biotechnology does

Amaran Biotechnology (潤雅生技) is a Taiwan-based contract development and manufacturing organization (CDMO) founded in April 2010 and headquartered in the Hsinchu Biomedical Science Park, Zhubei City. The company provides end-to-end biopharmaceutical manufacturing services to global vaccine developers, biotech, and pharmaceutical companies, organized around five service pillars: proprietary GMP-grade vaccine adjuvant AB-801 (a QS-21 equivalent derived from Quillaja saponaria); drug substance manufacturing covering glycoproteins, bio-conjugation, lyophilization, and advanced purification (preparative HPLC, MPLC, FPLC); drug product aseptic fill-finish using Taiwan's first fully automated robotic gloveless filling system (Cytiva/Vanrx SA25) supporting vials, pre-filled syringes, and cartridges at 99.99% filling precision; ICH-compliant stability and analytical services; and regulatory/supply chain consultation, with Water for Injection (WFI) services added through a January 2026 partnership with Cintrade.

The company operates from a PIC/S GMP-certified facility, re-certified in 2019, 2021, and September 2024, and as of December 2025 is the first adjuvant supplier in Taiwan to hold an FDA Type II Drug Master File Acknowledgement for AB-801. Technology infrastructure includes the Simploud electronic Quality Management System (eQMS) and a fully digitized Unitech Electronics Warehouse Management System designed for FDA 21 CFR Part 11 and DSCSA serialization compliance. Building C received Taiwan Ministry of Interior Green Building certification in July 2024.

Amaran is 67% owned by publicly listed OBI Pharma Inc. (4174.TWO on the Taipei Exchange), following a September 2020 share exchange; OBI Pharma is also a customer, with Amaran manufacturing API for OBI's immunotherapeutic products including Adagloxad Simolenin (OBI-822) and the BCVax COVID-19 vaccine. Revenue is generated through project-based CDMO contracts plus proprietary adjuvant sales; the company reported approximately 30% year-over-year revenue growth in 2024, with aseptic filling revenue growing 2.5x year-over-year through May 2024 and customer count roughly doubling since the 2022 launch of the automated filling line. The company markets primarily through major international industry events (BioJapan, BIO Asia-Taiwan, BIO International Convention) and BPIPO-organized Taiwan delegations.

Name

Amaran Biotechnology

Legal name

Amaran Biotechnology, Inc.

Website

https://amaran.com.tw

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Amaran Biotechnology is a Taiwan-based PIC/S GMP-certified CDMO providing drug substance manufacturing, automated robotic aseptic fill-finish, analytical services, and a proprietary QS-21 vaccine adjuvant (AB-801) to global vaccine developers and biopharmaceutical companies, majority-owned by OBI Pharma.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biopharmaceutical CDMO services
• Vaccine adjuvant manufacturing
• Aseptic fill-finish services
• Drug substance manufacturing
• Biologics contract manufacturing

Headquarters

HQ city

Hsinchu

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Contract Manufacturing Services: Provides end-to-end contract development and manufacturing services including process development, drug substance manufacturing, aseptic fill-finish, analytical services, and stability studies. Revenue is generated through project-based contracts with pharmaceutical and biotech companies. Growth is driven by increasing customer numbers and expanded service adoption.
2. Vaccine Adjuvant AB-801 (QS-21) Sales: Manufactures and sells proprietary GMP-grade high-purity vaccine adjuvant AB-801 to global pharmaceutical partners, research institutions, and vaccine manufacturers. Currently supplied to a leading global pharmaceutical company, with adoption across Europe, North America, China, and Japan.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Amaran Biotechnology is a next-generation Contract Development and Manufacturing Organization (CDMO) that provides integrated biopharmaceutical services to global vaccine developers and biotech companies. Its core offerings span five service pillars: (1) proprietary GMP-grade AB-801 (QS-21) vaccine adjuvant, (2) complex drug substance manufacturing including bio-conjugation, purification, and lyophilization, (3) automated aseptic fill-finish of drug product using Taiwan's first fully robotic gloveless isolation line (Vanrx SA25), (4) ICH stability and analytical services, and (5) regulatory and supply chain consultation. All services are delivered from a PIC/S GMP-certified facility in Hsinchu Biomedical Science Park, Taiwan.

Product overview

Amaran Biotechnology is a next-generation Contract Development and Manufacturing Organization (CDMO) providing integrated biopharmaceutical services. The company operates as a unified CDMO platform offering five interconnected service pillars: AB-801 Adjuvant (high-purity QS-21 vaccine adjuvant), Drug Substance Manufacturing (complex API production with bio-conjugation and purification capabilities), Drug Product Manufacturing (Taiwan's first automated robotic aseptic filling line), Stability Study & Analytical Services (comprehensive quality testing), and Sourcing & Consultation Services (supply chain and regulatory support). Additional offerings include Water for Injection (WFI) services. The company leverages advanced technologies including gloveless robotic isolator systems and digital quality management systems to serve global vaccine and biologics developers.

Differentiator

Problem solved

Functional benefit

Products and services

• AB-801 Vaccine Adjuvant (QS-21) GMP-grade, high-purity vaccine adjuvant (QS-21) derived from the Quillaja saponaria tree (native to Chile, Bolivia, and Peru). AB-801 enhances immune responses, improves vaccine efficacy, and reduces required antigen dosage, offering application characteristics comparable to widely used QS-21 adjuvant. Sold to global vaccine developers and research institutions across Europe, North America, China, Japan, and India.
• Drug Product Manufacturing (Aseptic Fill-Finish) State-of-the-art aseptic filling service featuring Taiwan's first fully automated robotic gloveless isolation system (Vanrx SA25 / Cytiva). Supports vials, pre-filled syringes, and cartridges (0.1–50 mL) at 99.99% filling precision. Single-use consumables eliminate cleaning validation and cross-contamination risk. For global vaccine developers and biologics manufacturers.
• Drug Substance Manufacturing Contract manufacturing of complex, high-value drug substances with capabilities including bio-conjugation, preparative HPLC/MPLC/FPLC purification, ozonization reactions, lyophilization, protein purification, and glycosylation reactions. Includes process scale-up and validation. For pharmaceutical and biotech clients needing API production.
• Stability Study & Analytical Services Comprehensive analytical support including ICH stability studies (storage conditions: -80°C, -20°C, 5°C, 25°C/60% RH, 40°C/75% RH), method development and validation, protein characterization (SEC-HPLC, IEC, ELISA, Western blot), residual solvent testing (GC-FID, GC-MS), and environmental monitoring. For pharmaceutical and biotech clients needing analytical and stability support.
• Sourcing & Consultation Services Consultation in supply chain management, quality assurance (cGMP regulatory consulting), regulatory affairs (drug registration technical documentation), and supplier development/auditing. For pharmaceutical and biotech clients needing regulatory and supply-chain support.
• Water for Injection (WFI) Services High-purity pharmaceutical-grade water production using STERIS Finn-Aqua multi-effect distillation technology, meeting cGMP, WHO, GAMP, and ASME BPE standards with endotoxin levels below 0.25 EU/ml. Delivered in partnership with Cintrade for the Taiwan biopharmaceutical industry.

Quantifiable outcome

• Aseptic filling revenue grew 2.5x year-over-year as of May 2024
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Cintrade (興全生醫)coreStrategic or Co-development Partner · 21 January 2026Amaran Biotech signed MOU with Cintrade to jointly expand Water for Injection (WFI) services for the biopharmaceutical industry in Taiwan. Amaran is responsible for manufacturing cGMP-grade WFI and performing analytical testing, stability studies, and compliance verification. Cintrade provides single-use system materials including filtration lines, WFI storage bags, logistics, and market promotion.
• Nippon Fine Chemical Co., Ltd.coreStrategic or Co-development Partner · 7 March 2025Amaran Biotech signed MOU with Nippon Fine Chemical and Zillion Fine Chemicals for nanoparticle-based drug CDMO manufacturing. Amaran provides its aseptic filling line and CDMO services to support Nippon Fine Chemical's production of nanoparticle-based drugs including liposomes and lipid nanoparticles (LNPs). Services include sterile filtration, aseptic filling, packaging, storage, and quality management. Collaboration aims to expand CDMO markets in Taiwan, Japan, and internationally.
• SimploudsupportingTechnology or Integration · 21 October 2024Simploud provides electronic Quality Management System (eQMS) to Amaran Biotech. Implementation includes eSOP module, Change Control, and Deviation modules for digital quality management supporting GxP compliance.
• Stellar Biotechnologies, Inc. (USA)coreStrategic or Co-development Partner · 1 March 2017Exclusive supply agreement for Keyhole Limpet Hemocyanin (KLH) for use in cancer immunotherapy vaccine manufacturing. KLH serves as a carrier protein for OBI Pharma's Adagloxad Simolenin (OBI-822) cancer vaccine. Stellar is responsible for maintaining the DMF with FDA for KLH products used by Amaran.
• Zillion Fine Chemicals International Co., Ltd.coreStrategic or Co-development PartnerTaiwan subsidiary of Nippon Fine Chemical, specializing in liposome technology with CRO and CDMO services. Partners with Amaran and Nippon Fine Chemical to provide comprehensive nanoparticle-based drug CDMO services in Taiwan.
• Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO)supportingGTM or Marketing PartnerBPIPO leads delegations of Taiwanese biotech companies to international exhibitions including BioJapan and BIO International Convention. Amaran participates in BPIPO-organized Taiwan Pavilions at major international events.
• Cytiva (Vanrx)supportingTechnology or IntegrationCytiva (formerly Vanrx) supplied the SA25 robotic aseptic filling system to Amaran Biotech. Amaran co-hosts technical workshops with Cytiva on advanced aseptic processing technologies for proteins and novel substances.
• OBI Pharma Inc. (Taiwan)coreStrategic or Co-development PartnerOBI Pharma is the parent company of Amaran Biotech. In September 2020, a share exchange was completed where OBI Pharma acquired 67% of Amaran shares. Amaran manufactures API for OBI Pharma's active immunotherapeutic products including Adagloxad Simolenin (OBI-822) and BCVax COVID-19 vaccine.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Cytovance Biologics: US-based biologics CDMO offering microbial and mammalian DS manufacturing and aseptic fill-finish. Comparable for biologics DS and fill-finish services targeted at vaccine, antibody, and protein programs.
• AGC Biologics: Global biologics CDMO with microbial and mammalian capabilities, including aseptic fill-finish. Comparable as a mid-sized global biologics CDMO competing for similar gene therapy, vaccine, and complex protein programs.
• Bora Pharmaceuticals: Taiwan-based CDMO with global sterile fill-finish and oral solid dose capabilities. Comparable as a Taiwan-headquartered CDMO serving international pharma, though Bora's scale and dosage-form breadth (larger commercial footprint) exceed Amaran's biologics focus.

Regional players

• ScinoPharm Taiwan: Taiwan-based API and CDMO provider focused on small molecules and select biologics. Comparable as a Taiwan-headquartered contract manufacturer serving international pharma, though primary focus is small-molecule APIs versus Amaran's biologics orientation.
• Eden Biologics: Taiwan-based biologics manufacturer and CDMO with biosimilar and bioanalytical capabilities. Comparable as a Taiwan-based biologics-focused CDMO serving similar Asia-Pacific biopharma customers, though with different therapeutic focus.

Broad incumbents

• Samsung Biologics: Korea-based biologics CDMO with very large-scale aseptic fill-finish capacity. Directly comparable as an Asia-Pacific biologics CDMO serving global pharma with similar PIC/S GMP regulatory standing, though at materially larger scale.
• WuXi Biologics: Global biologics CDMO leader offering end-to-end DS and DP services for mAbs, recombinant proteins, and bispecifics. Comparable service categories (biologics DS + fill-finish) but far larger scale and broader global footprint; competes for the same biologics outsourcing budgets.
• Lonza Biologics: One of the largest global biologics CDMOs offering mammalian and microbial DS, aseptic fill-finish, and integrated end-to-end services. Comparable service scope across DS/DP biologics; benchmark for scale and regulatory depth.
• Catalent: Global CDMO (now under Novo Holdings) and one of the largest aseptic fill-finish providers globally, including for biologics and vaccines. Directly comparable for sterile fill-finish services and a key reference for Amaran's automated robotic approach.

Others

• PharmaEssentia: Taiwan-based biopharmaceutical company using recombinant protein technology and contract manufacturing partners. Comparable as a Taiwan-headquartered biopharma working with similar CDMO networks, though it operates more as a product developer than a CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/amaran.biotech
• LinkedInlinkedin.com/company/amaran-biotechnology-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amaran Biotechnology